Medtronic PLC $MDT Stock Holdings Trimmed by Mairs & Power Inc.

Key Points

• Mairs & Power trimmed its stake in Medtronic by 5.4% in Q3, selling 24,718 shares and retaining 430,572 shares valued at about $41.01 million.
• Medtronic beat quarterly estimates, reporting $1.36 EPS (vs. $1.34 expected) and $9.02B revenue (up 5.8% YoY); it set FY2026 guidance of $5.62–$5.66 EPS and declared a $0.71 quarterly dividend (3.2% yield, ex-dividend Mar 27, payable Apr 17).

Mairs & Power Inc. lessened its holdings in shares of Medtronic PLC (NYSE:MDT - Free Report) by 5.4% in the third quarter, according to its most recent filing with the SEC. The firm owned 430,572 shares of the medical technology company's stock after selling 24,718 shares during the quarter. Mairs & Power Inc.'s holdings in Medtronic were worth $41,005,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of MDT. Delos Wealth Advisors LLC acquired a new position in Medtronic during the 2nd quarter valued at about $27,000. Corundum Trust Company INC acquired a new stake in shares of Medtronic in the 3rd quarter worth approximately $27,000. Valley Wealth Managers Inc. bought a new position in shares of Medtronic in the third quarter valued at approximately $29,000. Imprint Wealth LLC acquired a new position in shares of Medtronic during the third quarter valued at approximately $31,000. Finally, Steigerwald Gordon & Koch Inc. bought a new stake in Medtronic during the third quarter worth approximately $33,000. 82.06% of the stock is currently owned by institutional investors.

Medtronic Trading Up 1.1%

NYSE:MDT opened at $88.13 on Tuesday. The company has a market capitalization of $113.15 billion, a P/E ratio of 24.55, a P/E/G ratio of 2.24 and a beta of 0.71. The stock's 50 day moving average price is $97.77 and its 200 day moving average price is $96.88. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33.

Medtronic (NYSE:MDT - Get Free Report) last posted its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The firm had revenue of $9.02 billion during the quarter, compared to analysts' expectations of $8.89 billion. During the same period in the previous year, the company earned $1.38 earnings per share. The company's revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Investors of record on Friday, March 27th will be issued a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 3.2%. The ex-dividend date is Friday, March 27th. Medtronic's payout ratio is 79.11%.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the company's stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares of the company's stock, valued at $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.26% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Leerink Partners reaffirmed an "outperform" rating and set a $119.00 price target on shares of Medtronic in a research note on Tuesday, March 10th. The Goldman Sachs Group set a $111.00 price target on Medtronic and gave the stock a "neutral" rating in a research note on Wednesday, November 19th. William Blair raised shares of Medtronic from a "market perform" rating to an "outperform" rating in a research note on Tuesday, January 6th. Barclays reaffirmed an "overweight" rating and issued a $118.00 price objective on shares of Medtronic in a research note on Wednesday, February 18th. Finally, Royal Bank Of Canada boosted their target price on shares of Medtronic from $111.00 to $118.00 and gave the company an "outperform" rating in a research note on Wednesday, November 19th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $110.74.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.